• Contact
  • Location
  • Sitemap
  • DCprime Merger Information
    • Overview
    • Media
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
Immunicum
  • Contact
  • Location
  • Sitemap
  • DCprime Merger Information
    • Overview
    • Media
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
You are here:HomeInvestorsPress ReleasesPressreleases 2018

Investors

  • Overview
  • Press releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • Subscribe
  • Events & Presentations
  • Corporate Governance
    • Articles of Association
    • General meeting
    • Board of directors
    • Corporate governance reports
    • Senior Executives
    • Nomination Committee
    • Remuneration and the remuneration committee
    • Auditors and audit committee
    • Scientific committee
    • Scientific Advisory Board
  • Shareholder & Stock Info
    • Shareholders
    • Insider
    • Investment calculator
    • Share price look-up
  • Analyst Coverage
  • Financial Reports
  • Financial calendar
  • Secured Rights issue 2018
  • Secured Rights issue 2017
  • Downloads

Press releases 2018

  • All
  • Regulatory release

Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Directed Issue

28 December 2018 Read more R

Immunicum AB (publ) Publishes the Outcome in the Share Issues and Raises SEK 351M

13 December 2018 Read more R

Immunicum AB (publ) Publishes Prospectus in Connection with Rights Issue and Directed Issue

23 November 2018 Read more R

Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study

16 November 2018 Read more R

Report from Extraordinary General Meeting of Immunicum AB (publ) on 8 November 2018

8 November 2018 Read more R

Immunicum AB (publ) Interim Report July - September 2018

7 November 2018 Read more R

Immunicum AB: Invitation to Investor Events in Gothenburg and Stockholm

24 October 2018 Read more

Immunicum AB (publ) Announces Upcoming Investor Events in October and November

22 October 2018 Read more

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018

22 October 2018 Read more

Immunicum AB (publ) Announces Nomination Committee for AGM 2019

19 October 2018 Read more R

Immunicum AB (publ) Clarifies Information Regarding Directed Issue

16 October 2018 Read more R

Notice of Extraordinary General Meeting in Immunicum AB (publ)

16 October 2018 Read more R

Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel - a New and Innovative Cancer Immunotherapy

16 October 2018 Read more R

Immunicum AB (publ) Gives Information on Trading Halt and Ongoing Negotiations for a Potential Collaboration

1 October 2018 Read more R

Immunicum AB (publ) Announces Upcoming Presentations at Conferences in October

27 September 2018 Read more

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board

17 September 2018 Read more

Immunicum AB (publ) Interim Report April - June 2018

17 August 2018 Read more R

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress

13 August 2018 Read more

Immunicum AB (publ) Announces Protocol Approval by the FDA Enabling the Initiation of Expanded Multi-indication Phase Ib/II Combination Trial

23 July 2018 Read more R

Immunicum AB (publ) Announces Publication of Scientific Review of Ilixadencel Approach in Pharmaceutical Research

18 June 2018 Read more

Immunicum AB: Invitation to Investor Event

24 May 2018 Read more

Immunicum AB (publ) Announces End of Enrollment in Phase I/II GIST Clinical Trial

21 May 2018 Read more R

Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in May and June

14 May 2018 Read more

Immunicum AB (publ) Interim report January - March 2018

4 May 2018 Read more R

Report from the Annual General Meeting of Immunicum AB (publ) on April 25, 2018

25 April 2018 Read more R

Immunicum AB (publ) Publishes the Annual Report for 2017

3 April 2018 Read more R

Immunicum AB (publ) Provides Update on Ilixadencel Clinical Development Program

3 April 2018 Read more

Notice of Annual General Meeting in Immunicum AB (publ)

26 March 2018 Read more R

Immunicum AB: Invitation to Investor Events

21 March 2018 Read more

Immunicum AB: Immunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data

20 March 2018 Read more

Immunicum AB: The Nomination Committee of Immunicum AB (publ) proposes Michael Oredsson as new Chairman of the Board

14 March 2018 Read more R

Immunicum AB: The Nomination Committee of Immunicum AB (publ) proposes Michael Oredsson as new Chairman of the Board

14 March 2018 Read more R

Immunicum AB (publ) Year-End Report (October - December 2017) Corporate Update and Outlook

16 February 2018 Read more R

Immunicum AB (publ) Presents Case Study of One Patient from Phase I/II HCC Trial at Cholangiocarcinoma Foundation Annual Conference

5 February 2018 Read more

Michaela Gertz Joins Immunicum as CFO

31 January 2018 Read more R

Change in the Number of Shares and Votes in Immunicum

31 January 2018 Read more R

Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in January and February

22 January 2018 Read more

Immunicum AB (publ) Initiates Trading of Shares on Nasdaq Stockholm

15 January 2018 Read more

Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase II MERECA Trial

8 January 2018 Read more R

Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Directed Issue

28 December 2018 Read more R

Immunicum AB (publ) Publishes the Outcome in the Share Issues and Raises SEK 351M

13 December 2018 Read more R

Immunicum AB (publ) Publishes Prospectus in Connection with Rights Issue and Directed Issue

23 November 2018 Read more R

Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study

16 November 2018 Read more R

Report from Extraordinary General Meeting of Immunicum AB (publ) on 8 November 2018

8 November 2018 Read more R

Immunicum AB (publ) Interim Report July - September 2018

7 November 2018 Read more R

Immunicum AB (publ) Announces Nomination Committee for AGM 2019

19 October 2018 Read more R

Immunicum AB (publ) Clarifies Information Regarding Directed Issue

16 October 2018 Read more R

Notice of Extraordinary General Meeting in Immunicum AB (publ)

16 October 2018 Read more R

Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel - a New and Innovative Cancer Immunotherapy

16 October 2018 Read more R

Immunicum AB (publ) Gives Information on Trading Halt and Ongoing Negotiations for a Potential Collaboration

1 October 2018 Read more R

Immunicum AB (publ) Interim Report April - June 2018

17 August 2018 Read more R

Immunicum AB (publ) Announces Protocol Approval by the FDA Enabling the Initiation of Expanded Multi-indication Phase Ib/II Combination Trial

23 July 2018 Read more R

Immunicum AB (publ) Announces End of Enrollment in Phase I/II GIST Clinical Trial

21 May 2018 Read more R

Immunicum AB (publ) Interim report January - March 2018

4 May 2018 Read more R

Report from the Annual General Meeting of Immunicum AB (publ) on April 25, 2018

25 April 2018 Read more R

Immunicum AB (publ) Publishes the Annual Report for 2017

3 April 2018 Read more R

Notice of Annual General Meeting in Immunicum AB (publ)

26 March 2018 Read more R

Immunicum AB: The Nomination Committee of Immunicum AB (publ) proposes Michael Oredsson as new Chairman of the Board

14 March 2018 Read more R

Immunicum AB: The Nomination Committee of Immunicum AB (publ) proposes Michael Oredsson as new Chairman of the Board

14 March 2018 Read more R

Immunicum AB (publ) Year-End Report (October - December 2017) Corporate Update and Outlook

16 February 2018 Read more R

Michaela Gertz Joins Immunicum as CFO

31 January 2018 Read more R

Change in the Number of Shares and Votes in Immunicum

31 January 2018 Read more R

Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase II MERECA Trial

8 January 2018 Read more R
Press releases

Choose which language you would like to receive the press release in:

Swedish English
Contact us

Östermalmstorg 5
114 42 Stockholm
Sweden

Telephone

+46 (0)8 732 8400

Email

info@immunicum.com

For information about personal data processing at Immunicum, please see Immunicum´s Integrity Policy

Social
Links
  • Sitemap
  • Integrity and Cookie Policy

© 2002-2021 Immunicum AB. All rights reserved.

Designer mkmedia
To top

We use cookies to improve the user experience on Immunicum. Read more about Cookies

Approve